Not Signed In -
Haloperidol Tablets |
Haldol Tablets |
Clinical Trial: 5HT3 Antagonism and Auditory Gating in Schizophrenia
This study has been completed.
|
Purpose
The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.
| Condition | Treatment or Intervention |
|---|---|
| Schizophrenia | Drug: ondansetron Behavior: neuropsychological testing Drug: nicotine Drug: haloperidol |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study
Study start: June 1998; Study completion: June 2003
Eligibility
Ages Eligible for Study: 18 Years - 55 Years, Genders Eligible for Study: Both
Criteria
Location Information
Colorado
VAMC, Denver, Colorado, 80013, United States
More Information
Record last reviewed: December 2004
Last Updated: December 30, 2004
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018850
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Haldol Tablets (Drug Digest)
- Haloperidol Tablets (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
